Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
09 mai 2024 16h01 HE
|
Xenon Pharmaceuticals Inc.
Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in late 2024 to early 2025 Successful “end-of-Phase 2” interactions with FDA in MDD; Phase...
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
08 mai 2024 16h01 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will...
Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
07 mai 2024 16h01 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will...
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update
02 mai 2024 16h01 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, May 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced it will report its first...
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
16 avr. 2024 08h30 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced two oral presentations...
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
10 avr. 2024 08h30 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
04 avr. 2024 16h01 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
12 mars 2024 16h01 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, March 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
05 mars 2024 16h01 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, March 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
29 févr. 2024 16h01 HE
|
Xenon Pharmaceuticals Inc.
XEN1101 Phase 3 epilepsy program continues to progress with X-TOLE2 and X-TOLE3 in focal onset seizures and X-ACKT in primary generalized tonic-clonic seizures; completion of patient enrollment in...